Physician profile
Robert M Hall
NPI 1265691331
$1,008.19
in general payments reported to CMS, 2019-2025
15 companies · $91.15 in 2025
The $91.15 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $797 · 2022: $104 · 2024: $15.48 · 2025: $91.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $106.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $191.16 | 2021-2022 | |
| Glaxosmithkline, LLC. | $146.40 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.10 | 2021-2022 | |
| Novo Nordisk INC | $110.54 | 2021-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $106.46 | 2021-2022 | |
| Lilly USA, LLC | $83.11 | 2021 | |
| Dexcom, INC. | $60.34 | 2021 | |
| Astellas Pharma US INC | $33.97 | 2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $31.75 | 2021 | |
| Amgen INC. | $27.60 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $19.43 | 2022 | |
| Eisai INC. | $18.43 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.67 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.53 | 2021 | |
| Jazz Pharmaceuticals INC. | $11.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.